|
1
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 5:412–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomao F, Papa A, Zaccarelli E, Rossi L,
Caruso D, Minozzi M, Vici P, Frati L and Tomao S: Triple-negative
breast cancer: New perspectives for targeted therapies. Onco
Targets Ther. 8:177–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kubota Y: Tumor angiogenesis and
anti-angiogenic therapy. Keio J Med. 61:47–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH,
Chen YH, Jie TT, Lu YY and Liu JC: 12-Deoxyphorbol 13-palmitate
inhibit VEGF-induced angiogenesis via suppression of
VEGFR-2-signaling pathway. J Ethnopharmacol. 146:724–733. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goel HL and Mercurio AM: VEGF targets the
tumour cell. Nat Rev Cancer. 13:871–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimbro KS and Simons JW: Hypoxia-inducible
factor-1 in human breast and prostate cancer. Endocr Relat Cancer.
13:739–749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zbytek B, Peacock DL, Seagroves TN and
Slominski A: Putative role of HIF transcriptional activity in
melanocytes and melanoma biology. Dermatoendocrinology. 5:239–251.
2013. View Article : Google Scholar
|
|
8
|
Li M and Kim WY: Two sides to every story:
The HIF-dependent and HIF-independent functions of pVHL. J Cell Mol
Med. 15:187–195. 2011. View Article : Google Scholar :
|
|
9
|
Thomas GV, Tran C, Mellinghoff IK, Welsbie
DS, Chan E, Fueger B, Czernin J and Sawyers CL: Hypoxia-inducible
factor determines sensitivity to inhibitors of mTOR in kidney
cancer. Nat Med. 12:122–127. 2006. View
Article : Google Scholar
|
|
10
|
Liu L, Ning X, Han S, Zhang H, Sun L, Shi
Y, Sun S, Guo C, Yin F, Qiao T, et al: Hypoxia induced HIF-1
accumulation and VEGF expression in gastric epithelial mucosa cell:
Involvement of ERK1/2 and PI3K/Akt. Mol Biol. 42:459–469. 2008.In
Russian. View Article : Google Scholar
|
|
11
|
Paplomata E and O'Regan R: The
PI3K/AKT/mTOR pathway in breast cancer: Targets, trials and
biomarkers. Ther Adv Med Oncol. 6:154–166. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gomez-Pinillos A and Ferrari AC: mTOR
signaling pathway and mTOR inhibitors in cancer therapy. Hematol
Oncol Clin North Am. 26:483–505. vii2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moavero R, Coniglio A, Garaci F and
Curatolo P: Is mTOR inhibition a systemic treatment for tuberous
sclerosis? Ital J Pediatr. 39:572013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang J and Manning BD: The TSC1-TSC2
complex: A molecular switchboard controlling cell growth. Biochem
J. 412:179–190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fuckar D, Dekanić A, Stifter S, Mustać E,
Krstulja M, Dobrila F and Jonjić N: VEGF expression is associated
with negative estrogen receptor status in patients with breast
cancer. Int J Surg Pathol. 14:49–55. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahluwalia A and Tarnawski AS: Critical
role of hypoxia sensor - HIF-1α in VEGF gene activation.
Implications for angiogenesis and tissue injury healing. Curr Med
Chem. 19:90–97. 2012. View Article : Google Scholar
|
|
17
|
Mac Gabhann F, Qutub AA, Annex BH and
Popel AS: Systems biology of pro-angiogenic therapies targeting the
VEGF system. Wiley Interdiscip Rev Syst Biol Med. 2:694–707. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Serfontein J, Nisbet RE, Howe CJ and de
Vries PJ: Evolution of the TSC1/TSC2-TOR signaling pathway. Sci
Signal. 3:ra492010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weinstein IB and Joe AK: Mechanisms of
disease: Oncogene addiction - a rationale for molecular targeting
in cancer therapy. Nat Clin Pract Oncol. 3:448–457. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fakhrejahani E and Toi M: Antiangiogenesis
therapy for breast cancer: An update and perspectives from clinical
trials. Jpn J Clin Oncol. 44:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kerbel RS: Tumor angiogenesis: Past,
present and the near future. Carcinogenesis. 21:505–515. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reich SJ, Fosnot J, Kuroki A, Tang W, Yang
X, Maguire AM, Bennett J and Tolentino MJ: Small interfering RNA
(siRNA) targeting VEGF effectively inhibits ocular
neovascularization in a mouse model. Mol Vis. 9:210–216.
2003.PubMed/NCBI
|
|
24
|
Fox SB, Generali DG and Harris AL: Breast
tumour angiogenesis. Breast Cancer Res. 9:2162007. View Article : Google Scholar
|
|
25
|
Ventrice P, Leporini C, Aloe JF, Greco E,
Leuzzi G, Marrazzo G, Scorcia GB, Bruzzichesi D, Nicola V and
Scorcia V: Anti-vascular endothelial growth factor drugs safety and
efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 4(Suppl
1): S38–S42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bausero P, Ben-Mahdi M, Mazucatelli J,
Bloy C and Perrot-Applanat M: Vascular endothelial growth factor is
modulated in vascular muscle cells by estradiol, tamoxifen, and
hypoxia. Am J Physiol Heart Circ Physiol. 279:H2033–H2042.
2000.PubMed/NCBI
|
|
27
|
Xiao H, Gu Z, Wang G and Zhao T: The
possible mechanisms underlying the impairment of HIF-1α pathway
signaling in hyperglycemia and the beneficial effects of certain
therapies. Int J Med Sci. 10:1412–1421. 2013. View Article : Google Scholar
|
|
28
|
Chen MH, Ren QX, Yang WF, Chen XL, Lu C
and Sun J: Influences of HIF-lα on Bax/Bcl-2 and VEGF expressions
in rats with spinal cord injury. Int J Clin Exp Pathol.
6:2312–2322. 2013.
|
|
29
|
Yuan Y, Hilliard G, Ferguson T and
Millhorn DE: Cobalt inhibits the interaction between
hypoxia-inducible factor-α and von Hippel-Lindau protein by direct
binding to hypoxia-inducible factor-α. J Biol Chem.
278:15911–15916. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park SY, Jang WJ, Yi EY, Jang JY, Jung Y,
Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by
inhibiting HIF-1α stabilization under hypoxia. J Pineal Res.
48:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang N, Wang L, Esko J, Giordano FJ, Huang
Y, Gerber HP, Ferrara N and Johnson RS: Loss of HIF-1α in
endothelial cells disrupts a hypoxia-driven VEGF autocrine loop
necessary for tumorigenesis. Cancer Cell. 6:485–495. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahn GO, Seita J, Hong BJ, Kim YE, Bok S,
Lee CJ, Kim KS, Lee JC, Leeper NJ, Cooke JP, et al: Transcriptional
activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells
promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci
USA. 111:2698–2703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leung KW, Ng HM, Tang MK, Wong CC, Wong RN
and Wong AS: Ginsenoside-Rg1 mediates a hypoxia-independent
upregulation of hypoxia-inducible factor-1α to promote
angiogenesis. Angiogenesis. 14:515–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu N, Hui H, Yang H, Zhao K, Chen Y, You
QD and Guo QL: Gambogic acid inhibits angiogenesis through
inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci. 49:220–226.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiao N, Qi XY, Tang LN, Tan LL, Chen YQ
and Zhao HM: VEGF promotes cardiac stem cells differentiation into
vascular endothelial cells via the PI3K/Akt signaling pathway.
Artif Cells Nanomed Biotechnol. 42:400–405. 2014. View Article : Google Scholar
|
|
37
|
Agani F and Jiang BH: Oxygen-independent
regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in
cancer. Curr Cancer Drug Targets. 13:245–251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee SH, Jee JG, Bae JS, Liu KH and Lee YM:
A group of novel HIF-1α inhibitors, glyceollins, blocks HIF-1α
synthesis and decreases its stability via inhibition of the
PI3K/AKT/mTOR pathway and Hsp90 binding. J Cell Physiol.
230:853–862. 2015. View Article : Google Scholar
|
|
39
|
Fang J, Ding M, Yang L, Liu LZ and Jiang
BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Cell Signal. 19:2487–2497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang J, Dibble CC, Matsuzaki M and
Manning BD: The TSC1-TSC2 complex is required for proper activation
of mTOR complex 2. Mol Cell Biol. 28:4104–4115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Massacesi C, di Tomaso E, Fretault N and
Hirawat S: Challenges in the clinical development of PI3K
inhibitors. Ann NY Acad Sci. 1280:19–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
May FE: Novel drugs that target the
estrogen-related receptor α: Their therapeutic potential in breast
cancer. Cancer Manag Res. 6:225–252. 2014. View Article : Google Scholar
|
